Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-264-4280
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) issued its earnings results on Monday, July, 29th. The company reported ($1.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.88) by $0.36. View Rhythm Pharmaceuticals' Earnings History.
When is Rhythm Pharmaceuticals' next earnings date?
What price target have analysts set for RYTM?
5 analysts have issued 12 month price targets for Rhythm Pharmaceuticals' stock. Their forecasts range from $34.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $38.80 in the next year. This suggests a possible upside of 81.0% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals.
What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. LADENBURG THALM/SH SH analysts commented, "We’ve learned from management that the yield will be broken out by patient type. We continue to look for ~2,500 identified and diagnosed MC4R patients in the U.S., with roughly half of them being BBS patients (see Exhibit 4). While management has not provided its internal estimates, it has now stated the number of BBS/Alström patients has exceeded its expectations." (9/9/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and our $34 target price on RYTM shares after the company reported its 2Q19 financials and business update. As we highlighted in our recent upgrade note (here), at the current share price, we believe there is a favorable risk/reward ahead of the Phase 3 data readouts for setmelanotide in POMC and LEPR deficiency obesities which are expected in the coming weeks. We believe both Phase 3 studies will be positive and in our homerun" scenario the stock could move up to the low ~$40 range. Additionally, we believe the 4Q19 update from management on its ongoing patient identification efforts for POMC/LEPR and other MC4R pathway disorders remain an unappreciated catalyst investors should be tracking." (7/29/2019)
- 3. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (7/17/2019)
- 4. Needham & Company LLC analysts commented, "Rhythm reported 1Q19 financial results today and we spoke w/ mgmt for an update. Top-line results from setmelanotide Phase 3 trials in POMC and LEPR are expected 3Q19. We continue to expect positive outcomes based on impressive Phase 2 data. Rhythm is still opening sites in the setmelanotide Phase 3 trial in pts w/ but mgmt reiterated guidance for completing enrollment in 2H19 and results in 2H20. The company is assessing 6-12 other rare genetic obesity disorders for potential inclusion in the ongoing Phase 2 basket trial. An update is expected later this yr. Mgmt also plans to share more data from GO-ID obesity DNA sequencing study and TEMPO rare genetic obesity registry later this yr. BUY." (5/5/2019)
Has Rhythm Pharmaceuticals been receiving favorable news coverage?
Media coverage about RYTM stock has trended very negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Rhythm Pharmaceuticals.
Are investors shorting Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,310,000 shares, an increase of 30.3% from the August 30th total of 2,540,000 shares. Based on an average daily volume of 247,900 shares, the short-interest ratio is presently 13.4 days. Currently, 15.6% of the shares of the stock are sold short. View Rhythm Pharmaceuticals' Current Options Chain.
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include Nektar Therapeutics (NKTR), Emergent Biosolutions (EBS), Myokardia (MYOK), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Xencor (XNCR), Amicus Therapeutics (FOLD), Cambrex (CBM) and Ligand Pharmaceuticals (LGND).
What other stocks do shareholders of Rhythm Pharmaceuticals own?
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
- Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
- Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
- Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
- Mr. Simon D. Kelner, Chief HR Officer (Age 46)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
How do I buy shares of Rhythm Pharmaceuticals?
Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of RYTM stock can currently be purchased for approximately $21.44.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $739.96 million. The company earns $-74,060,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.View Additional Information About Rhythm Pharmaceuticals.
What is Rhythm Pharmaceuticals' official website?
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
